LEXINGTON, Mass.--(BUSINESS WIRE)--EPIX Pharmaceuticals, Inc. (NASDAQ:EPIX), a biopharmaceutical company focused on discovering and developing novel therapeutics through the use of its proprietary and highly efficient in silico drug discovery platform, today announced the formation of a Technology Advisory Board (TAB) that includes several leaders in the field of computational technologies. The EPIX TAB has been established to advise the company on key aspects of its computational technologies including EPIX’s proprietary in silico modeling for drug discovery. The charter members of the TAB, convening its inaugural session this week, include Charles L. Brooks, III, Ph.D., Johan Aqvist, Ph.D., and Gabriele Cruciani, Ph.D.
